Evgen reported interim results to 30 September that are in line with our full-year expectations. Despite the recent set back with SFX-01 in sub-arachnoid haemorrhage (SAH), the company continues to plan for a Phase IIb trial in metastatic breast cancer (mBC). Evgen is continuing to develop the CMC and toxicology data that will extend the dosing of SFX-01 in non-terminal diseases beyond 28 days, thereby opening up the potential of Phase II trials in autism and NASH, which are subject to non-di
17 Dec 2019
Evgen Pharma - Interims – cash to Q3 2021
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - Interims – cash to Q3 2021
Evgen Pharma Plc (EVG:LON) | 0.9 0 0.0% | Mkt Cap: 2.41m
- Published:
17 Dec 2019 -
Author:
Mark Brewer -
Pages:
10
Evgen reported interim results to 30 September that are in line with our full-year expectations. Despite the recent set back with SFX-01 in sub-arachnoid haemorrhage (SAH), the company continues to plan for a Phase IIb trial in metastatic breast cancer (mBC). Evgen is continuing to develop the CMC and toxicology data that will extend the dosing of SFX-01 in non-terminal diseases beyond 28 days, thereby opening up the potential of Phase II trials in autism and NASH, which are subject to non-di